MiNK Therapeutics Announces Strategic Collaboration with C-Further
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy INKT?
MiNK Therapeutics announced a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration between MiNK Therapeutics and C-Further will advance a T cell receptor-engineered invariant natural killer T cell therapy targeting PRAME, a tumor-associated antigen highly expressed across multiple pediatric and adult malignancies with limited expression in healthy tissues. By combining PRAME-specific antigen recognition with MiNK's iNKT cell platform, the program seeks to harness the biology of iNKT cells-immune effectors that bridge innate and adaptive immunity-to enable precise tumor targeting while also activating coordinated immune responses within the tumor microenvironment. Under the agreement, the MiNK program will receive approximately $1.1M in non-dilutive, aggregate funding to support IND-enabling development of its PRAME-TCR-iNKT asset, advancing the program through preclinical candidate nomination and key translational milestones, with payments tied to the completion of defined scientific milestones. The agreement also includes a double-digit share of downstream commercial revenues, reflecting the company's proprietary iNKT platform and its role in enabling next-generation TCR-based cellular therapies aligned with the objectives of the C-Further program. Importantly, the collaboration is non-exclusive, preserving MiNK's ability to continue advancing its iNKT platform independently and to pursue tumor antigen targets across oncology indications and partnerships. Under the collaboration, MiNK will serve as the lead industry partner, contributing its iNKT platform, engineering capabilities, and translational development expertise. Investigators at the University of Southampton will support independent, comparative preclinical studies to evaluate anti-tumor activity, persistence, and safety across multiple pediatric cancer models, including patient-derived tumor systems with the goal of nominating a single lead clinical candidate for advancement toward first-in-human studies in children.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.450
Low
35.00
Averages
35.00
High
35.00
Current: 10.450
Low
35.00
Averages
35.00
High
35.00
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
C-Further Advances Pediatric Cancer Therapeutics Initiatives
- Pediatric Cancer Treatment Breakthrough: C-Further, in collaboration with leading global academic and industry researchers, has launched early-stage therapeutic programs CF-012 and CF-033 targeting multiple children's cancers, including Ewing sarcoma, aiming to address significant gaps in pediatric cancer treatment.
- Funding and Collaborative Network: With an initial budget of $40 million (£30 million), C-Further is advancing CF-012 and CF-033 towards preclinical candidate nomination through partnerships with institutions like UVA Comprehensive Cancer Center and Dana-Farber Cancer Institute, ensuring the completion of scientific milestones.
- Innovative Treatment Mechanism: CF-012 targets the transcriptional dependency ETV6, aiming to develop a first-in-class inhibitor with a precise mechanism to disrupt tumor growth and metastasis, particularly addressing the urgent treatment needs for young patients with Ewing sarcoma.
- Future Development Plans: C-Further plans to announce additional programs in 2026 and welcomes expressions of interest from researchers and innovators to further advance personalized and well-tolerated treatments for childhood cancers.
See More
MiNK Therapeutics Secures $1.1 Million Funding for Pediatric Cancer Collaboration
- Funding Support: MiNK Therapeutics has secured approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset, which will significantly advance its efforts in pediatric cancer treatment.
- Revenue Sharing Agreement: The collaboration includes a double-digit share of downstream commercial revenues, which not only provides MiNK with a continuous income stream but also enhances its competitive position in the market.
- Innovative Treatment Platform: MiNK's iNKT cell therapy, as an allogeneic, off-the-shelf treatment, can be manufactured in advance and cryopreserved, ensuring timely access for patients without the need for HLA matching or toxic lymphodepleting chemotherapy.
- Clinical Data Validation: The clinical data published by MiNK in July 2025 indicates that a patient with metastatic testicular cancer achieved complete and durable remission following treatment with its iNKT cell therapy, demonstrating the therapy's efficacy and safety, thereby solidifying its position in the biopharmaceutical sector.
See More
MiNK Therapeutics Partners with C-Further for Pediatric Oncology
- Stock Surge: MiNK Therapeutics Inc. (INKT) shares soared by 73% in pre-market trading following the announcement of a strategic collaboration with C-Further, indicating strong market confidence in its iNKT cell therapy.
- Innovative Therapy Development: The collaboration aims to develop a TCR-engineered iNKT cell therapy targeting PRAME, an antigen relevant in various pediatric and adult cancers, particularly in pediatric sarcomas and acute myeloid leukemia, addressing critical treatment gaps.
- Funding and Commercial Terms: Under the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding for IND development, with milestone payments based on scientific progress, and a double-digit share of downstream commercial revenues, highlighting the value of its proprietary platform.
- Clinical Research and Future Outlook: Investigators at the University of Southampton will lead comparative preclinical studies to nominate a lead candidate for first-in-human trials in children, with MiNK's CEO emphasizing the collaboration's validation of its iNKT platform's maturity and potential in pediatric oncology.
See More
MiNK Therapeutics Stock Soars 60% on Key Collaboration with C-Further
- Stock Surge: MiNK Therapeutics (INKT) saw its stock price skyrocket over 60% during pre-market trading on Tuesday, primarily due to the announcement of a key collaboration with pediatric oncology consortium C-Further to develop a PRAME-targeted iNKT cell therapy for pediatric cancers.
- Funding Support: The collaboration provides MiNK with up to $1.1 million in non-dilutive funding for IND-enabling studies and preclinical milestones, alleviating financial pressure and offering robust support for subsequent research and development.
- Innovative Therapy: Dubbed CF-033, this program represents a potential first-in-class cell therapy that bridges innate and adaptive immunity, designed to enable both direct tumor cell killing and broader immune activation within the tumor microenvironment, highlighting its significant clinical application prospects.
- Strategic Importance: This collaboration marks one of C-Further's first selected programs since its launch by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity, demonstrating MiNK's strategic positioning and market potential in the pediatric cancer treatment landscape.
See More
MiNK Therapeutics Collaborates with C-Further on Pediatric Cancer Cell Therapy
- Stock Surge: MiNK Therapeutics (INKT) shares surged over 70% in pre-market trading on Tuesday, reflecting strong market optimism regarding the new collaboration, which could significantly enhance the company's market value and investor confidence.
- Project Launch: The company announced a partnership with C-Further oncology consortium to develop a cell therapy targeting pediatric cancers, focusing on PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy, aiming to precisely attack tumors while activating broader immune responses.
- Funding Support: The program will receive approximately $1.1 million in funding to support early-stage development, which not only secures financial backing for technological research but may also accelerate clinical trial processes, enhancing market competitiveness.
- Future Revenue Sharing: The agreement includes a double-digit share of future commercial revenues, which will provide potential long-term gains for the company, further boosting investor confidence in its growth prospects.
See More
MiNK Therapeutics Partners with C-Further to Develop Pediatric Cancer Therapy
- Strategic Collaboration Initiated: MiNK Therapeutics has partnered with C-Further, securing approximately $1.1 million in non-dilutive funding to advance a PRAME-targeted TCR-engineered iNKT cell therapy, reflecting a shared commitment to improving treatment options for pediatric cancers.
- Platform Advantages: This collaboration leverages MiNK's iNKT cell platform to precisely target the PRAME antigen, aiming to overcome limitations of traditional cell therapies by providing an off-the-shelf solution without HLA matching, thereby accelerating treatment and enhancing tolerability, particularly for children with aggressive cancers.
- Clinical Candidate Evaluation: Researchers from the University of Southampton will support independent comparative preclinical studies to assess the anti-tumor activity and safety of the therapy across various pediatric cancer models, ensuring the selection of the most suitable clinical candidate for advancement to first-in-human trials.
- Commercial Potential Outlook: The agreement includes a significant double-digit share of downstream commercial revenues, underscoring the importance of MiNK's iNKT platform in next-generation TCR-based cellular therapies, which is expected to generate substantial long-term revenue for the company.
See More
C-Further Advances Pediatric Cancer Therapeutics Initiatives
- Pediatric Cancer Treatment Breakthrough: C-Further, in collaboration with leading global academic and industry researchers, has launched early-stage therapeutic programs CF-012 and CF-033 targeting multiple children's cancers, including Ewing sarcoma, aiming to address significant gaps in pediatric cancer treatment.
- Funding and Collaborative Network: With an initial budget of $40 million (£30 million), C-Further is advancing CF-012 and CF-033 towards preclinical candidate nomination through partnerships with institutions like UVA Comprehensive Cancer Center and Dana-Farber Cancer Institute, ensuring the completion of scientific milestones.
- Innovative Treatment Mechanism: CF-012 targets the transcriptional dependency ETV6, aiming to develop a first-in-class inhibitor with a precise mechanism to disrupt tumor growth and metastasis, particularly addressing the urgent treatment needs for young patients with Ewing sarcoma.
- Future Development Plans: C-Further plans to announce additional programs in 2026 and welcomes expressions of interest from researchers and innovators to further advance personalized and well-tolerated treatments for childhood cancers.
See More
MiNK Therapeutics Secures $1.1 Million Funding for Pediatric Cancer Collaboration
- Funding Support: MiNK Therapeutics has secured approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset, which will significantly advance its efforts in pediatric cancer treatment.
- Revenue Sharing Agreement: The collaboration includes a double-digit share of downstream commercial revenues, which not only provides MiNK with a continuous income stream but also enhances its competitive position in the market.
- Innovative Treatment Platform: MiNK's iNKT cell therapy, as an allogeneic, off-the-shelf treatment, can be manufactured in advance and cryopreserved, ensuring timely access for patients without the need for HLA matching or toxic lymphodepleting chemotherapy.
- Clinical Data Validation: The clinical data published by MiNK in July 2025 indicates that a patient with metastatic testicular cancer achieved complete and durable remission following treatment with its iNKT cell therapy, demonstrating the therapy's efficacy and safety, thereby solidifying its position in the biopharmaceutical sector.
See More
MiNK Therapeutics Partners with C-Further for Pediatric Oncology
- Stock Surge: MiNK Therapeutics Inc. (INKT) shares soared by 73% in pre-market trading following the announcement of a strategic collaboration with C-Further, indicating strong market confidence in its iNKT cell therapy.
- Innovative Therapy Development: The collaboration aims to develop a TCR-engineered iNKT cell therapy targeting PRAME, an antigen relevant in various pediatric and adult cancers, particularly in pediatric sarcomas and acute myeloid leukemia, addressing critical treatment gaps.
- Funding and Commercial Terms: Under the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding for IND development, with milestone payments based on scientific progress, and a double-digit share of downstream commercial revenues, highlighting the value of its proprietary platform.
- Clinical Research and Future Outlook: Investigators at the University of Southampton will lead comparative preclinical studies to nominate a lead candidate for first-in-human trials in children, with MiNK's CEO emphasizing the collaboration's validation of its iNKT platform's maturity and potential in pediatric oncology.
See More
MiNK Therapeutics Stock Soars 60% on Key Collaboration with C-Further
- Stock Surge: MiNK Therapeutics (INKT) saw its stock price skyrocket over 60% during pre-market trading on Tuesday, primarily due to the announcement of a key collaboration with pediatric oncology consortium C-Further to develop a PRAME-targeted iNKT cell therapy for pediatric cancers.
- Funding Support: The collaboration provides MiNK with up to $1.1 million in non-dilutive funding for IND-enabling studies and preclinical milestones, alleviating financial pressure and offering robust support for subsequent research and development.
- Innovative Therapy: Dubbed CF-033, this program represents a potential first-in-class cell therapy that bridges innate and adaptive immunity, designed to enable both direct tumor cell killing and broader immune activation within the tumor microenvironment, highlighting its significant clinical application prospects.
- Strategic Importance: This collaboration marks one of C-Further's first selected programs since its launch by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity, demonstrating MiNK's strategic positioning and market potential in the pediatric cancer treatment landscape.
See More
MiNK Therapeutics Collaborates with C-Further on Pediatric Cancer Cell Therapy
- Stock Surge: MiNK Therapeutics (INKT) shares surged over 70% in pre-market trading on Tuesday, reflecting strong market optimism regarding the new collaboration, which could significantly enhance the company's market value and investor confidence.
- Project Launch: The company announced a partnership with C-Further oncology consortium to develop a cell therapy targeting pediatric cancers, focusing on PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy, aiming to precisely attack tumors while activating broader immune responses.
- Funding Support: The program will receive approximately $1.1 million in funding to support early-stage development, which not only secures financial backing for technological research but may also accelerate clinical trial processes, enhancing market competitiveness.
- Future Revenue Sharing: The agreement includes a double-digit share of future commercial revenues, which will provide potential long-term gains for the company, further boosting investor confidence in its growth prospects.
See More
MiNK Therapeutics Partners with C-Further to Develop Pediatric Cancer Therapy
- Strategic Collaboration Initiated: MiNK Therapeutics has partnered with C-Further, securing approximately $1.1 million in non-dilutive funding to advance a PRAME-targeted TCR-engineered iNKT cell therapy, reflecting a shared commitment to improving treatment options for pediatric cancers.
- Platform Advantages: This collaboration leverages MiNK's iNKT cell platform to precisely target the PRAME antigen, aiming to overcome limitations of traditional cell therapies by providing an off-the-shelf solution without HLA matching, thereby accelerating treatment and enhancing tolerability, particularly for children with aggressive cancers.
- Clinical Candidate Evaluation: Researchers from the University of Southampton will support independent comparative preclinical studies to assess the anti-tumor activity and safety of the therapy across various pediatric cancer models, ensuring the selection of the most suitable clinical candidate for advancement to first-in-human trials.
- Commercial Potential Outlook: The agreement includes a significant double-digit share of downstream commercial revenues, underscoring the importance of MiNK's iNKT platform in next-generation TCR-based cellular therapies, which is expected to generate substantial long-term revenue for the company.
See More
